Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.

[1]  A. Wells,et al.  Prostate cancer liver metastasis: Dormancy and resistance to therapy. , 2020, Seminars in cancer biology.

[2]  Jun Luo,et al.  Androgen receptor variant-driven prostate cancer II: advances in clinical investigation , 2020, Prostate Cancer and Prostatic Diseases.

[3]  Tian Zhang,et al.  Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. , 2020, Clinical genitourinary cancer.

[4]  F. Saad,et al.  Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[5]  Jun Luo,et al.  Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[6]  A. Plesa,et al.  Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. , 2019, European urology oncology.

[7]  F. Boccardo,et al.  Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients , 2019, Cancers.

[8]  S. Tomlins,et al.  Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer , 2019, Neoplasia.

[9]  S. Gregory,et al.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Weichselbaum,et al.  Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.

[11]  A. Azmi,et al.  Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression , 2018, Oncotarget.

[12]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[13]  F. Saad,et al.  Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY , 2018, Clinical Cancer Research.

[14]  David S. K. Lu,et al.  Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer , 2018, JAMA oncology.

[15]  K. Nutahara,et al.  AR‐V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration‐resistant prostate cancer patients , 2018, The Prostate.

[16]  K. Pantel,et al.  In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. , 2018, Clinical chemistry.

[17]  P. Rosenberg,et al.  Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. , 2017, European urology focus.

[18]  David S. K. Lu,et al.  Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. , 2017, European urology.

[19]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Jenster,et al.  The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.

[21]  E. Scarpi,et al.  Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer , 2016, PloS one.

[22]  W. Figg,et al.  Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion? , 2016, Cancer biology & therapy.

[23]  R. Montironi,et al.  AR-V7 and prostate cancer: The watershed for treatment selection? , 2016, Cancer treatment reviews.

[24]  S. Sleijfer,et al.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. , 2015, European urology.

[25]  R. Montironi,et al.  The origin of prostate metastases: emerging insights , 2015, Cancer and Metastasis Reviews.

[26]  J. Luo,et al.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Jun Luo,et al.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. , 2015, JAMA oncology.

[28]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[29]  Jochen K. Lennerz,et al.  Detecting predictive androgen receptor modifications in circulating prostate cancer cells , 2015, Oncotarget.

[30]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[31]  R. Vessella,et al.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer. , 2012, Cancer research.

[32]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[33]  A Laupacis,et al.  Assessing the quality of randomized trials: reliability of the Jadad scale. , 1999, Controlled clinical trials.